Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that it has published results from its Phase II GEMINI study in the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE